A perspective on risks that impede development of drugs to modify the course of Alzheimer's disease: Can they be reduced?

Alzheimer's and Dementia

Volumn 4, Issue 1 SUPPL. 1, 2008, Pages

  Mohs, Richard C ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

Clinical trials; Drug development; Policy; Regulation

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEW DRUG; NOOTROPIC AGENT; RIVASTIGMINE;

ALZHEIMER DISEASE; ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; DISEASE COURSE; DRUG APPROVAL; DRUG EFFICACY; DRUG INDICATION; DRUG INDUSTRY; DRUG MARKETING; DRUG MECHANISM; DRUG RESEARCH; DRUG SAFETY; DRUG SCREENING; DRUG SYNTHESIS; DRUG TREATMENT FAILURE; GOVERNMENT; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; RISK REDUCTION;

ALZHEIMER DISEASE; BRAIN; CLINICAL TRIALS AS TOPIC; DRUG APPROVAL; HUMANS; RISK;

EID: 38049130003     PISSN: 15525260     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jalz.2007.11.011     Document Type: Article

References (12)

1. Center for Drug Evaluation and Research. Number of NDAs received by calendar year (2007), US Food and Drug Administration, Rockville, MD. http://www.fda.gov/cder/rdmt/numofndareccy.htm Available at: www.fda.gov/cder/rdmt/numofndareccy.htm. Accessed: November 2, 2007
2. Center for Drug Evaluation and Research. NDAs approved by calendar years 1990-2004 (2005), US Food and Drug Administration, Rockville, MD. http://www.fda.gov/cder/rdmt/pstable.htm Available at: www.fda.gov/cder/rdmt/pstable.htm. Accessed: November 2, 2007
3. Center for Drug Evaluation and Research. 2007 CDER update (2007), US Food and Drug Administration, Rockville, MD
4. DiMasi J.A., Hansen R.W., and Grabowski H.G. The price of innovation: new estimates of drug development costs. Journal of Health Economics 22 (2003) 151-185
5. Pisano G.P. Science business (2006), Harvard Business School Press, Boston
6. Mohs R.C., Kawas C., and Carrillo M.C. Perspective: optimal design of clinical trials for drugs designed to show the course of Alzheimer's disease. Alzheimer's & Dementia 2 (2006) 131-139
7. Selkoe D.J. Alzheimer disease: mechanistic understanding predicts novel therapies. Ann Intern Med 140 (2004) 627-638
8. De Angelis C., Drazen J.M., Frizelle F.A., Haug C., Hoey J., Horton R., et al. Clinical trial registration: a statement from the international committee of medical journal editors. Ann Intern Med 141 (2004) 477-478
9. Leber P. Guidelines for the clinical evaluation of anti-dementia drugs. first draft (1990), US Food and Drug Administration, Rockville, MD
10. Flemming T.R., and DeMets D.L. Surrogate end points in clinical trials: are we being misled?. Ann Intern Med 125 (1996) 605-613
11. McConnell S., Karlawish J., Vellas B., and DeKosky S. Perspectives on assessing benefits and risks in clinical trials for Alzheimer's disease. Alzheimer's & Dementia 3 (2006) 160-163
12. Therasse P., Carbonnelle S., and Bogaerts J. Clinical trials design and treatment tailoring: general principles applied to breast cancer research. Crit Rev Oncol/Hematol 59 (2006) 98-105